On Wednesday, Shares of Viacom, Inc. (NASDAQ:VIAB), gained 0.98% to $41.18.
Viacom Inc. (NASDAQ:VIAB, VIA) has been notified of an unsolicited “mini-tender” offer by TRC Capital Corporation (TRC) to purchase up to 2,500,000 shares of Viacom Class B common stock at a price of $38.88 per share. The offer price is about 4.7% below the closing price of Viacom’s Class B shares on December 22, 2015, the day before commencement of the offer, and about 5.6% below recently’s closing price of $41.18. The offer is for about 0.72% of the outstanding Class B shares of Viacom common stock as of November 4, 2015.
Viacom does not endorse TRC’s unsolicited mini-tender offer and recommends that shareholders do not tender their shares. Viacom recommends that shareholders exercise caution with respect to TRC’s unsolicited mini-tender offer, and notes that the offer price is below Viacom’s current share price. Viacom also notes that the offer is subject to the satisfaction of a substantial number of conditions, counting the absence of any decrease in the market price of the company’s shares from the price on the date of the offer and the ability of TRC to finance the offer. If the market price of Viacom shares falls or TRC cannot obtain financing, TRC is permitted to terminate the offer and not purchase any shares.
Viacom strongly encourages shareholders to obtain current market quotations for their shares, and to consult with their broker or financial advisor. Shareholders who already have tendered their shares are advised that they may withdraw their shares by providing the written notice described in the TRC offering documents before the expiration of the offer, presently planned for 12:01 a.m. eastern time on Friday, January 22, 2016.
Viacom, Inc. operates as an entertainment content company in the United States and internationally. The company creates television programs, motion pictures, short-form content, applications, games, consumer products, social media, and other entertainment content.
Shares of Honeywell International Inc. (NYSE:HON), inclined 0.77% to $104.96, during its last trading session.
Honeywell International Inc., declared that Terrence Hahn, President and CEO, Honeywell Transportation Systems, will be presenting at the Deutsche Bank Global Auto Industry Conference in Detroit, Mich. on Tuesday, January 12, 2016 from 2:20 p.m. – 3:00p.m. EST.
Honeywell International Inc. operates as a diversified technology and manufacturing company worldwide. Its Aerospace segment provides aircraft engines, integrated avionics, systems and service solutions, and related products and services for aircraft manufacturers and operators, airlines, military services, and defense and space contractors; and spare parts, and repair and maintenance services for the aftermarket.
Finally, Valeant Pharmaceuticals Intl Inc (NYSE:VRX), ended its last trade with 1.65% gain, and closed at $114.99.
Pharming Group N.V. and its partner, Hyupjin Corporation, a Seoul based South Korean specialty pharma company, declare that Hyupjin has received the marketing authorisation for RUCONEST® (recombinant human C1 inhibitor) in South Korea. RUCONEST is approved for the treatment of acute angioedema attacks in adult patients with hereditary angioedema HAE. Effectiveness was not established in HAE patients with laryngeal and oro-pharyngeal attacks. Hyupjin will now seek reimbursement for RUCONEST in South Korea.
Sijmen de Vries, CEO of Pharming, commented: “Hyupjin is a well-established and practiced company with a proven track record in South Korea. We look forward to them now extending the commercialisation of RUCONEST by providing HAE patients in South Korea with a new, safe and effective treatment to treat their HAE atttacks.”
Choon Duk Kim, General Manager of Hyupjin Corporation, said: “RUCONEST is the first approved recombinant C1 esterase inhibitor worldwide and this approval of RUCONEST will now enable us to provide the Korean HAE patients access to this most innovative way to treat their disease. We fully appreciate all the supports from Pharming Group for the approval of RUCONEST in South Korea and we look forward to getting started.”
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, in addition to Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.